This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2011 by Hôpital Universitaire Fattouma Bourguiba.
Recruitment status was:  Recruiting
Information provided by:
Hôpital Universitaire Fattouma Bourguiba Identifier:
First received: May 10, 2011
Last updated: May 12, 2011
Last verified: May 2011

Evaluation of systematic administration of oral prednisolone (1mg/Kg/day) as an add on therapy in Chronic Obstructive Pulmonary Disease (COPD) patients admitted to intensive care unit (ICU) for severe exacerbation of COPD. Patients with pneumonia are excluded.

Randomization is stratified according to ventilatory support: non invasive or conventional ventilation.The major outcome is the ICU mortality rate in overall population and stratified according to ventilatory mode (noninvasive ventilation (NIV) versus conventional).

Secondary outcomes are superinfection necessitating a new antibiotic course, Length of mechanical ventilation (MV) (and ventilatory free days), Length of ICU stay, The frequency of gastric bleeding episodes that of frequency of hyperglycemic episodes.

Condition Intervention Phase
COPD Exacerbation Drug: Prednisolone Drug: usual care Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: A Prospective Randomized Trial of Systemic Corticosteroids (Oral Prednisolone) in Severe Exacerbation of COPD Requiring Ventilatory Assistance

Resource links provided by NLM:

Further study details as provided by Hôpital Universitaire Fattouma Bourguiba:

Primary Outcome Measures:
  • ICU mortality rate [ Time Frame: ICU stay (on average patients will be followed 30 days) ]

Secondary Outcome Measures:
  • Length of MV (and ventilatory free days) [ Time Frame: ICU stay (on average patients will be followed 30 days) ]

Estimated Enrollment: 200
Study Start Date: April 2010
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: usual care
patients will receive usual care
Drug: usual care
no drug administered
Active Comparator: Prednisolone
1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days
Drug: Prednisolone
Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All COPD patients (according to the ATS definition) experiencing acute exacerbation originating in acute respiratory failure and requiring ICU admission will be included in the study.

COPD exacerbation is defined by the increased frequency of cough, volume and purulence of sputum and that of wheeze.

Acute respiratory failure is defined by the presence of hypercapnia with PaCO2 >45mmHg associated with pH > 7.35 and signs of respiratory muscle fatigue (contraction of accessory respiratory muscles, thoracoabdominal swinging ,..).

Exclusion Criteria:

  • Asthmatic patients defined by a reversible obstructive disease following nebulized bronchodilators,
  • Patients with uncontrolled left heart failure,
  • AECOPD patients with a radiologically documented pneumonia,
  • Systemic corticotherapy within 30 days before screening,
  • contra-indication to corticosteroids (active gastroduodenal ulcer, uncontrolled sepsis, etc. ..)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01353235

Contact: Fekri Abroug, MD +21673460672

CHU F.Bourguiba Recruiting
Monastir, Tunisia, 5000
Contact: Fekri Abroug, MD    +21673460672   
Sub-Investigator: Lamia Besbes, MD         
Sub-Investigator: Fahmi Dachraoui, MD         
Sub-Investigator: Islem Ouanes, MD         
Sponsors and Collaborators
Hôpital Universitaire Fattouma Bourguiba
Principal Investigator: Fekri Abroug, MD CHU F.Bourguiba Monastir
  More Information

Responsible Party: Health Ministery, CHU F.Bourguiba Monastir Identifier: NCT01353235     History of Changes
Other Study ID Numbers: steroids in COPD exacerbation
Study First Received: May 10, 2011
Last Updated: May 12, 2011

Keywords provided by Hôpital Universitaire Fattouma Bourguiba:
acute respiratory failure
mechanical ventilation
non invasive ventilation

Additional relevant MeSH terms:
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents processed this record on July 24, 2017